122 related articles for article (PubMed ID: 35594697)
1. Internal dosimetry studies of
Sahafi-Pour SA; Shirmardi SP; Saeedzadeh E; Baradaran S; Sadeghi M
Appl Radiat Isot; 2022 Aug; 186():110273. PubMed ID: 35594697
[TBL] [Abstract][Full Text] [Related]
2. Assessment of MIRD data for internal dosimetry using the GATE Monte Carlo code.
Parach AA; Rajabi H; Askari MA
Radiat Environ Biophys; 2011 Aug; 50(3):441-50. PubMed ID: 21573984
[TBL] [Abstract][Full Text] [Related]
3. Preclinical voxel-based dosimetry through GATE Monte Carlo simulation using PET/CT imaging of mice.
Gupta A; Lee MS; Kim JH; Park S; Park HS; Kim SE; Lee DS; Lee JS
Phys Med Biol; 2019 Apr; 64(9):095007. PubMed ID: 30913544
[TBL] [Abstract][Full Text] [Related]
4. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
5. Internal dosimetry studies of
Shirmardi SP; Saniei E; Das T; Noorvand M; Erfani M; Bagheri R
Appl Radiat Isot; 2020 Dec; 166():109396. PubMed ID: 32889376
[TBL] [Abstract][Full Text] [Related]
6. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Application of Tissue-Specific Dose Kernels Instead of Water Dose Kernels in Internal Dosimetry: A Monte Carlo Study.
Khazaee Moghadam M; Kamali Asl A; Geramifar P; Zaidi H
Cancer Biother Radiopharm; 2016 Dec; 31(10):367-379. PubMed ID: 27996311
[TBL] [Abstract][Full Text] [Related]
8. Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma.
Narwadkar YS; Parghane RV; Sahu S; Lad S; Deep K; Wanage G; Suralkar T; Banerjee S; Gupta S; Basu S; Badwe RA
Clin Nucl Med; 2024 Apr; 49(4):e149-e155. PubMed ID: 38350067
[TBL] [Abstract][Full Text] [Related]
9. Primary radiation dosimetry of a novel PET radiopharmaceutical
Cheki M; Gali H
Hell J Nucl Med; 2017; 20(3):241-246. PubMed ID: 29177263
[TBL] [Abstract][Full Text] [Related]
10. Validation of GATE for bone and bone marrow with calculation specific absorbed fraction for photons.
Ghaseminezhad SZ; Sadremomtaz A; Rajabi H
J Cancer Res Ther; 2018; 14(3):647-650. PubMed ID: 29893333
[TBL] [Abstract][Full Text] [Related]
11. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [
Kurth J; Krause BJ; Schwarzenböck SM; Bergner C; Hakenberg OW; Heuschkel M
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):123-135. PubMed ID: 31482426
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of a new bombesin analog for imaging of gastrin-releasing peptide receptors.
Shirmardi SP; Gandomkar M; Maragheh MG; Shamsaei M
Cancer Biother Radiopharm; 2011 Jun; 26(3):309-16. PubMed ID: 21711115
[TBL] [Abstract][Full Text] [Related]
13. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
Smith CJ; Gali H; Sieckman GL; Hayes DL; Owen NK; Mazuru DG; Volkert WA; Hoffman TJ
Nucl Med Biol; 2003 Feb; 30(2):101-9. PubMed ID: 12623108
[TBL] [Abstract][Full Text] [Related]
14. Estimation of Human Absorbed Dose of
Vosoughi S; Salek N; Yousefnia H; Delavari M; Reza Aghamiri SM; Ranjbar H
Curr Radiopharm; 2023; 16(1):64-70. PubMed ID: 36121093
[TBL] [Abstract][Full Text] [Related]
15. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy.
Konijnenberg M; Melis M; Valkema R; Krenning E; de Jong M
J Nucl Med; 2007 Jan; 48(1):134-42. PubMed ID: 17204710
[TBL] [Abstract][Full Text] [Related]
16. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
[TBL] [Abstract][Full Text] [Related]
18. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.
Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Clin Nucl Med; 2018 May; 43(5):323-330. PubMed ID: 29485430
[TBL] [Abstract][Full Text] [Related]
19. A dose point kernel database using GATE Monte Carlo simulation toolkit for nuclear medicine applications: comparison with other Monte Carlo codes.
Papadimitroulas P; Loudos G; Nikiforidis GC; Kagadis GC
Med Phys; 2012 Aug; 39(8):5238-47. PubMed ID: 22894448
[TBL] [Abstract][Full Text] [Related]
20. Internal dosimetry of [
Fois GR; Valla C; Jouberton E; Sas N; Billoux T; Auzeloux P; Cachin F; Miot-Noirault E; Maigne L
Med Phys; 2021 Jan; 48(1):477-487. PubMed ID: 33217001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
